Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin

Muscle-invasive Bladder Cancer Clinical Trial

— NITIMIB  

Official title:

Neoadjuvant Immunotherapy With Durvalumab in Combination With Tremelimumab in Patients With Muscle-invasive Bladder Cancer Ineligible for Cisplatin-based Chemotherapy.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03234153
• Other study ID #: NITIMIB-Trial
• Status: Terminated
• Phase: Phase 2
• Start date: July 15, 2018
• Est. completion date: May 18, 2020

Study information

• Verified date: June 2020
• Source: University Hospital Inselspital, Berne
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The trial assess the safety and antitumor activity of the anti-PD-L1 antibody Durvalumab in combination with the anti-CTLA4 antibody Tremelimumab.

Description:

Background and Rationale:

The outcome for patients with muscle-invasive bladder cancer treated with surgery alone remains dismal with a 5 year survival rate between 25% to 80% depending on the tumor stage and lymph node status. Cisplatin-based chemotherapy regimens (Methotrexate, Vinblastine, Doxorubicin, Cisplatin ; Cisplatin, Methotrexate, Vinblastine; Gemcitabine/Cisplatin) have demonstrated a modest but absolute benefit in overall survival of 5-8% when administered in the neoadjuvant setting. Therefore, neoadjuvant Cisplatin-based regimens are regarded as a standard of care in treating patients with muscle-invasive bladder cancer. However, bladder cancer is a disease of the elderly and due to age-associated factors (e.g. hearing impaired ≥ grade 2), peripheral neuropathy (≥ grade 2), disease associated impairment of renal function (Glomerular filtration rate < 60 mL/min) and performance status (ECOG ≥ 2) 30 to 50% are ineligible for cisplatin-based chemotherapy regimens. Several combinations with Carboplatin have been tested in single arm, phase II trials in patients ineligible for Cisplatin but no standard regimen has been established for this patient population thus far. The Guidelines of the European association of Urology (EAU) do not recommend any neoadjuvant treatment for Cisplatin-ineligible patients.

The advent of immune checkpoint inhibitors like Durvalumab or Azetolizumab, both antibodies blocking the PD1/PD-L1 interaction, have shown promising results as single agents in terms of response (15-46%) and tolerability in the metastatic setting of bladder cancer.

A trial evaluating the safety, tolerability and antitumor activity of the combination of the immune-checkpoint inhibitors Durvarlumab and the anti-CTLA4 antibody Tremelimumab in various solid tumors, including urothelial carcinoma of the bladder is ongoing (protocol D4190C0010). Blocking the PD1/PD-L1 pathway in combination with an anti-CTLA4 antibody has shown greater antitumor activity than each antibody alone in malignant melanoma trials and showed a promising antitumor activity (17% overall response rate, irrespective of the PD-L1 expression status on tumor cells) in a phase Ib study of metastatic non-small-cell lung cancer. The safety profile was acceptable (42% grade 3-4 treatment related adverse events across all dosing cohorts, most common were diarrhea, colitis and increase lipase), however, the rate of adverse events (e.g. autoimmune phenomena) and treatment interruptions was higher as compared to single agent use.

Objective:

The Primary objective of the trial is to assess the safety and antitumor activity of the anti-PD-L1 antibody Durvalumab in combination with the anti-CTLA4 antibody Tremelimumab.

Study Duration:

Trial study duration encompassed the time from when the participant signs the informed consent until the last protocol-specific procedure has been completed (Cystectomy between week 17 to 23). All patients will be followed up for up to 78 weeks after end of treatment.

This study will be conducted in compliance with the protocol, the current version of the Declaration of Helsinki, the ICH-GCP as well as all national legal and regulatory requirements.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. completion date: May 18, 2020
• Est. primary completion date: November 8, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years

• Signed Informed Consent Form

• ECOG performance status of 0 or 1

• Histologically confirmed muscle-invasive urothelial carcinoma of the bladder (T2-T4 and/or N+). Patients with mixed histologies are required to have a dominant transitional cell pattern.

• Measurable disease according to RECIST v1.1 criteria

• Representative fresh tumor specimen; TURB (transurethral resection of bladder ) specimens must contain a muscle invasive component (at least T2)

• Ineligible to receive cisplatin-based neoadjuvant chemotherapy based on at least one of the following criteria:

• Creatinin clearance less than 60ml/min (24h urine)

• CTCAE Gr = 2 hearing loss

• CTCAE Gr = 2 neuropathy

• Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up

• Body weight >30 kg

• Adequate hematologic and end-organ function, defined by the following laboratory results obtained within 14 days prior the first study treatment:

• Absolute neutrophil count (ANC) = 1500 cells/µl

• WBC counts > 2500/µl

• Platelet count = 100,000/µl

• Hemoglobin = 9.0 g/dL

• AST, ALT and alkaline phosphatase = 2.5 times the upper limit of normal (ULN)

• Serum bilirubin = 1.5 x ULN

• INR and aPTT = 1.5 x ULN

• Serum creatinine clearance (CrCl) = 40 mL/min using the Cockcroft-Gault equation

• Evidence of post-menopausal status or negative urinary or serum pregnancy test for premenopausal female. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.

Exclusion Criteria:

• Known metastatic disease

• Intravesical chemo- or biological/immune (BCG) therapy within 6 weeks of first treatment dose

• Prio treatment with immune checkpoint blockade therapies like anti-CTLA-4, anti-PD1 and anti-PD-L1 therapeutic antibodies, including durvalumab and tremelimumab

• History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid syndrome, Wegner's granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome, multiple sclerosis, vasculitis or glomerulonephritis Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone are eligible for this study. Patients with controlled Type I diabetes mellitus on a stable dose of insulin regimen are eligible for this study

• Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of investigational drug.

• Female patients who are pregnant or breast feeding as well as male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy.

• Known allergy or hypersensitivity to any of the investigational study drugs or any of the study excipients.

• Prior randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment.

• Uncontrolled intercurrent illness, including but limited to, ongoing infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.

• Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 3 months, unstable arrhythmias, or unstable angina.

• Patients with prior allogeneic stem cell or solid organ transplantation

• History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan

• Positive test for HIV

• Patients with active hepatitis B (defined as having a positive hepatitis B surface antigen test at screening) or hepatitis C.

• Active tuberculosis

• Administration of a living, attenuated vaccine within 4 weeks prior to treatment start

• Severe infection within 4 weeks prior to cycle 1, day 1

• Treatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior treatment start or anticipated requirement for systemic immunosuppressive medications during the trial. The use of inhaled corticosteroids, physiologic replacement doses of glucocorticoids, and mineralocorticoids is allowed

• Known allergy or hypersensitivity to any of the study drugs or any of the study excipients.

Related Conditions & MeSH terms

• Muscle-invasive Bladder Cancer
• Urinary Bladder Neoplasms

Intervention

Drug:
• Durvalumab (Imfinzi)
Durvalumab 1500 mg i.v. every 4 weeks in combination with Tremelimumab 75 mg i.v. every 4 weeks for a total of 4 cycles before surgery.
• Tremelimumab
Tremelimumab 75 mg i.v. in combination with Durvalumab 1500 mg i.v. every 4 weeks every 4 weeks for a total of 4 cycles before surgery.

Locations

Country	Name	City	State
Switzerland	Departement of Medical Oncology, University Hospital Berne	Berne

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital Inselspital, Berne	AstraZeneca

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate	Response rate (computer tomography or magnet resonance imaging) as measured per standard RECIST v1.1 after four cycles of combined treatment with Durvalumab (MEDI4736) and tremelimumab.	16 weeks
Secondary	Adverse Events	Number of Patients experiencing Toxicity/Adverse Events (AE)	26 weeks
Secondary	Recurrence-free Survival	Number of Patients with Recurrence-free Survival at 78 weeks	78 weeks
Secondary	Overall Survival	Number of Patients alive at 78 weeks	78 weeks